Is Concordia Healthcare Corp. Too Cheap to Ignore?

Want a cheap company with exceptional growth potential? Consider Concordia Healthcare Corp. (TSX:CXR)(NASDAQ:CXRX)! But is there a catch?

The Motley Fool

Talk about a highly volatile stock! Within a year, Concordia Healthcare Corp. (TSX:CXR)(NASDAQ:CXRX) has declined more than 60% from over $100 to $40 per share today. In fact, in just a single day on May 31 Concordia’s shares fell more than 7%.

At today’s share price, Concordia trades at a forward multiple of four. Is it too cheap to ignore?

First, let’s get a sense of its business.

The business

Concordia owns a diversified portfolio of branded and generic prescription products. It has three operating segments, including Concordia North America, Concordia International, and Orphan Drugs.

The Concordia North America segment focuses predominantly on the U.S. pharmaceutical market. Its North American portfolio consists of branded products and authorized generic contracts.

Products include Donnatal, which treats irritable bowel syndrome, Nilandron, which treats metastatic prostate cancer, Lanoxin, which treats mild to moderate heart failure and atrial fibrillation, and more.

The Concordia International segment consists of Amdipharm Mercury Limited (AMCo), which was acquired by Concordia in October 2015. It focuses on acquiring, licensing, and developing off-patent prescription medicines that are niche or hard-to-make products.

AMCo has a diversified portfolio of branded and generic products that it sells to wholesalers, hospitals, and pharmacies in more than 100 countries.

Sales

In the first quarter that ended on March 31, Concordia earned revenue of US$228.5 million; 37.6% came from the North America segment, 61.2% came from the International segment, and 1.2% came from the Orphan Drugs segment.

Revenue was 570% higher than the first quarter of 2015. However, it’s difficult to compare the results of these quarters because of the AMCo and Corvis acquisitions that both occurred after March last year.

That said, its corporate and operating costs only went up 539% in comparison.

Debt and liquidity

The concern for investors is likely that Concordia primarily used debt to fund the acquisitions. As of March 31, 2016, the company sits on $3.3 billion of long-term debt; about 31% of Concordia’s debt has a maturity date within five years.

The company believes that operating cash flows should offer sufficient liquidity to support the company’s business operations for at least the next 12 months.

Additionally, if there’s a need for liquidity, Concordia can draw up to $200 million from a secured revolving loan.

Conclusion

Concordia financed its acquisitions primarily through debt. The heavy debt has weighed on its shares, which only trade at a forward multiple of four.

As its acquisitions show success and as Concordia pays off its debt, it will move progressively higher. However, there’s no question that it is riskier than the average stock with a debt-to-cap ratio of 74% and an S&P credit rating of only B, which is not investment grade.

If you’re looking for growth and can take on above-average risk, Concordia may fit in your diversified portfolio. Personally though, I wouldn’t bet the farm on it.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Kay Ng owns shares of CONCORDIA HEALTHCARE CORP.

More on Dividend Stocks

young woman celebrating a victory while working with mobile phone in the office
Dividend Stocks

3 CRA Benefits Most Canadians Can Grab in 2024

You can save on taxes by claiming the dividend tax credit on Fortis Inc (TSX:FTS) shares.

Read more »

Two seniors float in a pool.
Dividend Stocks

TFSA: How to Earn $1,890 in Annual Tax-Free Income

Plunk these investments into your TFSA to earn passive income and avoid the taxman.

Read more »

Engineers walk through a facility.
Dividend Stocks

1 TSX Stock I Wouldn’t Touch With a 10-Foot Pole

AtkinsRéalis (TSX:ATRL) is one TSX stock I'd never invest in.

Read more »

edit Woman in skates works on laptop
Dividend Stocks

3 No-Brainer Stocks to Buy Under $30

These three stocks all offer a huge deal for investors looking for dividends, as well as growth that will last.

Read more »

You Should Know This
Dividend Stocks

How to Convert a $300 Monthly Investment Into $338 in Monthly Income

If you want a certain amount in monthly passive income, invest a similar amount today and leave the rest to…

Read more »

Increasing yield
Dividend Stocks

3 Income Stocks With Big Yields to Consider in April 2024

If you haven’t yet made your March investments, here are three income stocks to buy the dip and lock in…

Read more »

Senior Man Sitting On Sofa At Home With Pet Labrador Dog
Dividend Stocks

RRSP Investors: Don’t Miss Out on This Contribution Hack!

This hack has so many benefits for you -- not just when you put it in your RRSP but for…

Read more »

A red umbrella stands higher than a crowd of black umbrellas.
Dividend Stocks

Passive Income: 2 Safe Dividend Stocks to Own for the Next 10 Years

Dividend stocks such as Manulife and Fortis can help you generate a stable and recurring passive-income stream.

Read more »